Drug Database
CO

colistimethate sodium (Colistineb / Colobreathe / Colomycin injection)

✓ Approved

Forest Laboratories Inc. · 治疗药物

什么是 colistimethate sodium?

colistimethate sodium 是一种治疗药物,由Forest Laboratories Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled、Injectable (Others)、Intravenous (IV)。

药物档案

商品名Colistineb, Colobreathe, Colomycin injection
公司Forest Laboratories Inc.
给药途径Inhaled, Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

colistimethate sodium 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPneumonia pseudomonal✓ Approved

相关研究文献

PubMedBMC public health2026-11-19

Association of sodium intake with incident asthma and the modifying role of potassium: insights from a prospective study.

Huang Wufeng W, Hukportie Daniel Nyarko DN, Kang Jing J, Li Wen W et al.

Emerging evidence suggests that high dietary salt intake may contribute to the development of immune-mediated diseases, including asthma. However, the relationship between salt consumption and the risk of adult-onset asthma, as well as how it may be influenced by other dietary electrolytes, remains unclear. This study aimed to clarify the association between salt intake and asthma risk, with particular attention to the potential interaction with urinary potassium levels. We conducted a prospective cohort study of 373,647 adults from the UK Biobank who were free of asthma at baseline. Salt intake was evaluated using two complementary approaches: a subjective measure based on the self-reported frequency of adding salt to foods, and an objective estimate of 24-h sodium excretion derived from spot urine samples. Urinary potassium levels were also measured from spot urine samples and used as an indicator of potassium status. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between salt intake and asthma incidence, adjusting for multiple potential confounding factors, and to assess potential effect modification by spot urinary potassium concentrations. Over a median follow-up period of 15.4 years, we documented 10,511 incident asthma cases. Compared with those who never or rarely added salt, participants who reported always adding salt had a 27% higher risk of asthma (HR 1.27, 95% CI 1.17-1.38). Each 1-g/day increase in estimated 24-h sodium excretion was associated with a 15% higher asthma risk in men and a 39% higher risk in women. Spline analyses further showed a progressively increasing asthma risk with higher estimated 24-h sodium excretion, with a notably steeper gradient at lower spot urinary potassium concentrations and a modest attenuation at higher levels, supporting a potential sodium-potassium interaction in relation to asthma risk (P for interaction < 0.05). In this large cohort study, both self-reported high salt-adding habits and higher estimated 24-h sodium excretion were associated with an increased incidence of asthma. Notably, higher spot urinary potassium concentrations appeared to attenuate the adverse effects of high sodium on asthma risk, suggesting that a combined dietary strategy of reducing salt intake while maintaining adequate potassium may help lower the risk of adult-onset asthma.

PMID 43052935
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Machine Learning-Driven Electrolyte Additive Discovery for Ultrafast Charging of Sodium Metal Batteries.

Ye Yuanchang Y, Cheng Li L, Zou Minyi M, Dong Yingxia Y et al.

Sodium metal batteries hold immense promise for large-scale, high-power storage systems, yet their fast charging is severely constrained by sluggish Na+ transport across unstable electrode-electrolyte interphases. Conventional fluorine-donating additives suffer from inefficient self-decomposition, inevitably generating resistive organic byproducts. Herein, we propose an active machine learning framework based on Gaussian process regression to develop an innovative additive-triggered anion decomposition pathway. Guided by iterative screening of key physicochemical descriptors, a trace-level (0.02 M) sodium chlorodifluoroacetate (NaCDFA) additive is successfully identified. Theoretical calculations combined with in situ characterizations reveal that the NaCDFA thermodynamically promotes the targeted and continuous decomposition of the PF6- anion, enabling the construction of robust and highly conductive NaF-rich interphases, which substantially reduces the Na+ migration barrier. Consequently, the Na||Na3V2(PO4)3 cell achieves ultrastable cycling over 50,000 cycles at an extreme rate of 200 C. Furthermore, outstanding performance is retained under rigorous practical conditions, including high-mass-loading cathodes and limited sodium excess or anode-free architectures. This work establishes a cost-effective trace-level electrolyte additive strategy for engineering fast-charging interphases, and demonstrates the transformative potential of machine learning-guided materials discovery for advancing battery technology.

PMID 43053434
阅读全文 →
PubMedBMC nephrology2026-11-19

Correction: Characteristics of sodium and water retention in rats with nephrotic syndrome induced by puromycin aminonucleoside.

Xu Zaiping Z, Wang Yunlai Y, Feng Ye Y, Yang Mo M et al.

PMID 43052858
阅读全文 →
PubMedBioscience reports2026-11-19

Retraction: RNA-Seq analysis reveals critical transcriptome changes caused by sodium butyrate in DN mouse models.

Yang Hansen H, Zhang Zheng Z, Peng Rui R, Zhang Luyu L et al.

PMID 43053622
阅读全文 →
PubMedBMC neurology2026-11-19

Therapeutic regimen for AD-derived MCI: the effect of sodium oligomannate (GV-971) combined with donepezil on patients' cognitive function and hippocampal atrophy rate.

Jiao Fucheng F, Li Yuhua Y, Zhang Lina L, Fang Caixia C et al.

To investigate the clinical efficacy of sodium oligomannate (GV-971) combined with donepezil in the treatment of patients with mild cognitive impairment (MCI) in Alzheimer's disease (AD). This non-randomized, open-label, retrospective analytic study included 100 patients with AD-derived MCI who were treated in our hospital between May 2023 and May 2024, and were divided into two groups according to the different treatment modalities recorded in the electronic medical record system: 44 cases in the control group (donepezil), and 56 cases in the observation group (sodium oligomannate (GV-971) combined with donepezil). Cognitive function, biochemical markers (homocysteine (Hcy), S100 calcium binding protein B (S100β), neuron-specific enolase (NSE)), serum intestinal flora metabolic markers (phenylalanine (Phe), short-chain fatty acids (SCFA), γ-aminobutyric acid (GABA), acetylcholine (Ach)), hippocampal volume, and adverse effects were collected and compared between the two groups, and adverse reactions were recorded. After treatment, the comparison of various scores of cognitive function, Hcy, S100β, NSE, Phe, SCFA, GABA, and Ach between the patients in the observation group and the control group showed statistically significant differences (P<0.05); after treatment, the comparison of left hippocampal volume, right hippocampal volume, and total volume between the observation group and the control group did not show any statistically significant difference (P>0.05). In contrast, the calculated hippocampal atrophy rate-derived from the percentage change relative to baseline volume-was significantly lower in the observation group than in the control group (P < 0.05). Regarding safety, the total incidence of adverse reactions was 10.71% (6/56) in the observation group versus 9.09% (4/44) in the control group, with no statistically significant difference between the two groups (P > 0.05). The combination of sodium oligomannate (GV-971) and donepezil was associated with more favorable changes in cognitive function, neuronal injury biomarkers, serum markers of gut microbiota metabolism, and a slower observed rate of hippocampal atrophy in patients with AD-derived MCI. These associations do not imply causation, and the combination regimen did not significantly increase adverse reactions in this cohort.

PMID 43052811
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Orbital-Enabled Intrinsic Defect Healing via Charge Compensation toward Accelerated Sodium Storage in Mn-Rich Composite Phosphates.

Teng Hao H, Teng Qipeng Q, Song Zihan Z, Xu Rui R et al.

Manganese-rich composite phosphate cathodes, represented by Na4Fe1.25Mn1.75(PO4)2P2O7 (NFMPP), offer high energy density for sodium-ion batteries. However, their limited electrochemical durability and sluggish kinetics hinder practical application. In this work, we first identify abundant intrinsic oxygen vacancies, which are determined to be responsible for the occurrence of Mn/Na antisite defects and deteriorate electrochemical performance of NFMPP. Building on the new insight, we design a trace V-doped Mn-rich composite phosphate cathode, Na4Fe1.25Mn1.65V0.1(PO4)2P2O7 (NFMPP-V). Different from other dopants (Cr3+, Co2+, Ni2+, Nb5+), the unique empty eg*0 orbitals and modest charge compensation (Δz = +1) of V3+ effectively reduce the oxygen-vacancy defects in the NFMPP structure. This reduction leads to a more uniform strain distribution and a lower concentration of in situ formed Mn/Na anti-site defects, ultimately accelerating Na+ kinetics and enabling more complete utilization of the intrinsic low-voltage Fe3+/Fe2+ redox reaction. Consequently, NFMPP-V can deliver an energy density of 421.1 Wh/kg, relating to a reversible capacity of 125.7 mAh g-1 with an enhanced initial Coulombic efficiency of 97.0% (105.8 mAh g-1, 87.0% for the NFMPP), outperforming most Mn-rich composite phosphate cathodes reported to date. Notably, a full pouch cell paired with a hard-carbon anode retains 93.6% of its capacity after 1000 cycles. This work clarifies the decisive role of oxygen-vacancy defects in Mn-rich composite phosphate cathodes and provides a new insight for developing high-performance sodium-ion batteries.

PMID 43053429
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多colistimethate sodium